false
IDEXX LABORATORIES INC /DE
0000874716
0000874716
2024-11-20
2024-11-20
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of report (Date of earliest event reported): November 20, 2024
IDEXX
LABORATORIES, INC.
(Exact
name of registrant as specified in its charter)
| Delaware |
|
000-19271 |
|
01-0393723 |
| (State
or other jurisdiction |
|
(Commission
File Number) |
|
(IRS
Employer Identification No.) |
| of
incorporation) |
|
|
|
|
| One IDEXX Drive, Westbrook, Maine |
|
|
|
04092 |
(Address
of principal executive offices) |
|
|
|
(ZIP
Code) |
207.556.0300
(Registrant's
telephone number, including area code)
Not
Applicable
(Former
name or former address, if changed since last report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):
| |
¨ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
¨ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities
registered pursuant to Section 12(b) of the Act:
| Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
| Common
Stock, $0.10 par value per share |
|
IDXX |
|
NASDAQ
Global Select Market |
Indicate
by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of
1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
| Item 5.02. | Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
Compensatory Arrangements of Certain Officers. |
On November 20, 2024, Brian P. McKeon, Executive
Vice President, Chief Financial Officer and Treasurer of IDEXX Laboratories, Inc. (the “Company” or “IDEXX”)
notified the Company that he will retire from IDEXX effective June 1, 2025. Mr. McKeon has served as the Company’s Executive
Vice President, Chief Financial Officer and Treasurer since January 2014 and was previously a member of the Company’s Board
of Directors (the “Board”) from July 2003 through December 2013.
Mr. McKeon will cease serving as the Company’s
Chief Financial Officer, Treasurer, principal financial officer and principal accounting officer, effective March 1, 2025, and will
serve as Executive Vice President and Special Advisor to the Company from March 1, 2025, until his retirement on June 1, 2025,
to help ensure a smooth and seamless transition. Mr. McKeon’s oversight responsibility for the Company’s Water, Livestock,
Poultry and Dairy and OPTI Medical businesses will transfer to Michael Lane, the Company’s Executive Vice President and General
Manager, Reference Laboratories and Information Technology, effective January 1, 2025.
On November 20, 2024, the Board appointed
Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance of the Company, as Executive
Vice President, Chief Financial Officer and Treasurer of the Company, effective March 1, 2025. In that role, Mr. Emerson will
serve as the Company’s principal financial officer and principal accounting officer.
Mr. Emerson, age 41, has served as a Senior
Vice President of the Company since January 2024 and a Vice President of the Company from November 2015 to December 2023.
Since joining IDEXX in November 2015, he has led the finance organization for the CAG business. In March 2020, he also assumed
responsibility for the corporate finance function, including investor relations, treasury, financial planning and analysis and financial
reporting.
Prior to joining IDEXX, Mr. Emerson served
as Vice President, Finance and Business Unit Controller at Medtronic plc, a global leader in healthcare technology. He joined Medtronic
through its acquisition of Covidien plc, a global healthcare technology and medical supplies provider, where he held finance positions
of increasing seniority, including Controller for the Advanced Surgical Technologies business unit. He holds a bachelor’s degree
in accounting and business management from Northeastern University.
As the Company’s Executive Vice President,
Chief Financial Officer and Treasurer, Mr. Emerson will: (i) be paid an annual base salary of $550,000; (ii) participate
in the Company’s annual Executive Incentive Plan with a fiscal 2025 target cash bonus of 75% of base salary; (iii) be eligible
to receive grants of annual equity awards under the Company’s 2018 Stock Incentive Plan, as amended (the “Plan”), subject
to requisite Board approval and the terms and conditions of the Plan and the applicable equity award agreements and in accordance with
the Company’s guidelines for his position; and (iv) be entitled to change in control benefits pursuant to a change in control
agreement with substantially the same terms and conditions as the current change in control agreement with Mr. McKeon in his capacity
as the Company’s chief financial officer, and as more fully described in the “Executive Compensation – Potential Payments
Upon Termination or Change in Control – (4) Change in Control” section of the Company’s Proxy Statement filed with
the Securities and Exchange Commission on March 27, 2024.
There are no arrangements or understandings between
Mr. Emerson and any other persons pursuant to which he was appointed to serve as the Company’s Executive Vice President, Chief
Financial Officer and Treasurer. Mr. Emerson has no direct or indirect material interest in any transaction required to be disclosed
pursuant to Item 404(a) of Regulation S-K, and Mr. Emerson has no family relationships with any director or executive officer
of the Company.
| Item 7.01 | Regulation FD Disclosure. |
A copy of the press release dated November 21,
2024 announcing these matters is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
| Item 9.01. | Financial Statements and Exhibits. |
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| |
|
IDEXX LABORATORIES, INC. |
| |
|
|
| |
|
|
| Date: November 21, 2024 |
By: |
/s/ Sharon E. Underberg |
| |
|
Sharon E. Underberg |
| |
|
Executive Vice President, General Counsel and Corporate Secretary |
Exhibit 99.1
IDEXX
Announces CFO Transition
Brian McKeon to Retire from IDEXX in June 2025
Andrew Emerson, Senior Vice President, Corporate
and CAG Finance, to Serve as IDEXX’s Next CFO
WESTBROOK, Maine, November 21, 2024 — IDEXX Laboratories, Inc.
(NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that Brian McKeon has decided to retire from IDEXX effective
June 1, 2025. Andrew Emerson, currently Senior Vice President, Corporate and Companion Animal Group (“CAG”) Finance,
will succeed Mr. McKeon as IDEXX’s Executive Vice President, Chief Financial Officer and Treasurer, effective March 1,
2025. Mr. McKeon will serve as EVP and Special Advisor to the Company from March 1, 2025 until his retirement from IDEXX on
June 1, 2025, to help ensure a smooth and seamless transition.
“Andrew brings nearly 20 years of broad financial experience
to his new role, as well as nine years of deep and intimate knowledge of our strategy and finances, working side by side with Brian, making
him a natural fit to succeed Brian as CFO,” said Jay Mazelsky, IDEXX’s President and Chief Executive Officer. “Andrew
has been deeply involved in virtually all aspects of CAG finance since 2015, and has helped achieve significant growth for the Company,
with CAG now generating more than 90% of IDEXX’s total revenue. He also has overseen our corporate finance areas since 2020, including
financial reporting, investor relations, tax, treasury, and financial planning and analysis. IDEXX has significant opportunities to continue
expanding our reach, driving innovation, delivering for our customers and executing on business development initiatives, while creating
long-term value for our shareholders and other stakeholders. We are confident Andrew is the right person to help drive our next phase
of growth and profitability.”
“I am honored to be named IDEXX’s CFO-elect, and look forward
to building on IDEXX’s momentum,” said Mr. Emerson. “With a strong financial foundation and clear strategic drivers,
the Company is well-positioned to continue growing revenue, increasing profitability and delivering long-term value. I am excited to lead
the finance organization and look forward to working closely with Brian as I transition into the CFO role.”
Mr. Mazelsky added, “On behalf of the Board and management
team, I thank Brian for his leadership, guidance and partnership. Brian has been a true asset to IDEXX for more than two decades,
having first served as a Director on our Board before stepping into the CFO role ten years ago. With Brian’s help and oversight,
we have delivered outstanding financial results, expanded our global footprint and executed a disciplined capital allocation strategy.
IDEXX is in a position of strength today, poised for continued success, and we wish Brian the very best in his next chapter.”
“It has been the highlight of my career to work alongside the
talented team at IDEXX, and I am proud of all we have accomplished together,” said Mr. McKeon. “Since joining IDEXX first
as a Director in 2003, and then as CFO in 2014, I have been honored to play a part in the growth of IDEXX and development of solutions
that are enhancing the health and well-being of pets, people and livestock. IDEXX is fortunate to have a strong and talented leader like
Andrew as the Company’s next CFO. I look forward to watching the Company’s continued success for many years to come.”
The Company also reaffirmed its 2024 full year guidance as provided
on October 31, 2024.
About Andrew Emerson
Andrew Emerson joined IDEXX in November 2015, and has led the
finance organization for the CAG business since that time. In March 2020, he also assumed responsibility for the corporate finance
function, including investor relations, financial planning and analysis, accounting, tax and treasury.
Prior to joining IDEXX, Mr. Emerson served as Vice President,
Finance and Business Unit Controller at Medtronic plc, a global leader in healthcare technology. He joined Medtronic through its acquisition
of Covidien plc, a global healthcare technology and medical supplies provider, where he held finance positions of increasing seniority,
including Controller for the Advanced Surgical Technologies business unit. He holds a bachelor’s degree in accounting and business
management from Northeastern University.
About IDEXX Laboratories, Inc.
IDEXX is a global leader in pet healthcare innovation. Our diagnostic
and software products and services create clarity in the complex, constantly evolving world of veterinary medicine. We support longer,
fuller lives for pets by delivering insights and solutions that help the veterinary community around the world make confident decisions—to
advance medical care, improve efficiency, and build thriving practices. Our innovations also help ensure the safety of milk and water
across the world and maintain the health and well-being of people and livestock. IDEXX Laboratories, Inc. is a member of the S&P
500® Index. Headquartered in Maine, IDEXX employs approximately 11,000 people and offers solutions and products
to customers in more than 175 countries and territories. For more information about IDEXX, visit idexx.com.
Note Regarding Forward-Looking Statements
This news release
contains or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including
statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking
statements can be identified by the use of words such as “expects,” “may,” “anticipates,” “intends,”
“would,” “will,” “plans,” “believes,” “estimates,” “should,”
“project,” and similar words and expressions. Our forward-looking statements include statements relating to our expectations
regarding our previously issued 2024 full year guidance; future financial performance; revenue and profitability growth; our belief in
our ability to create long-term value for our shareholders and other stakeholders; and our ability to execute a smooth and seamless CFO
transition. These forward-looking statements are intended to provide our current expectations or forecasts of future events; are based
on current estimates, projections, beliefs, and assumptions; and are not guarantees of future performance. Actual events or results may
differ materially from those described in the forward-looking statements. These forward-looking statements involve known and unknown
risks and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially
different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things,
the matters described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's
Discussion and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About
Market Risk" in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 and in the corresponding
sections of the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2024, June 30, 2024, and September 30,
2024, respectively, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange
Commission available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement,
whether as a result of new information, future events or otherwise.
Contact
Media Relations
media@idexx.com
Investor Relations
investorrelations@idexx.com
v3.24.3
| X |
- DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission.
| Name: |
dei_AmendmentFlag |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.
| Name: |
dei_DocumentPeriodEndDate |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:dateItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
| Name: |
dei_DocumentType |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:submissionTypeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionAddress Line 1 such as Attn, Building Name, Street Name
| Name: |
dei_EntityAddressAddressLine1 |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- Definition
+ References
+ Details
| Name: |
dei_EntityAddressCityOrTown |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCode for the postal or zip code
| Name: |
dei_EntityAddressPostalZipCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the state or province.
| Name: |
dei_EntityAddressStateOrProvince |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:stateOrProvinceItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityCentralIndexKey |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:centralIndexKeyItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionIndicate if registrant meets the emerging growth company criteria. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityEmergingGrowthCompany |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
| Name: |
dei_EntityFileNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:fileNumberItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTwo-character EDGAR code representing the state or country of incorporation.
| Name: |
dei_EntityIncorporationStateCountryCode |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarStateCountryItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityRegistrantName |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b-2
| Name: |
dei_EntityTaxIdentificationNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:employerIdItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionLocal phone number for entity.
| Name: |
dei_LocalPhoneNumber |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:normalizedStringItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 13e
-Subsection 4c
| Name: |
dei_PreCommencementIssuerTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 14d
-Subsection 2b
| Name: |
dei_PreCommencementTenderOffer |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTitle of a 12(b) registered security. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
| Name: |
dei_Security12bTitle |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:securityTitleItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionName of the Exchange on which a security is registered. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
| Name: |
dei_SecurityExchangeName |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:edgarExchangeCodeItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Section 14a
-Number 240
-Subsection 12
| Name: |
dei_SolicitingMaterial |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionTrading symbol of an instrument as listed on an exchange.
| Name: |
dei_TradingSymbol |
| Namespace Prefix: |
dei_ |
| Data Type: |
dei:tradingSymbolItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
| X |
- DefinitionBoolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act. Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 230
-Section 425
| Name: |
dei_WrittenCommunications |
| Namespace Prefix: |
dei_ |
| Data Type: |
xbrli:booleanItemType |
| Balance Type: |
na |
| Period Type: |
duration |
|
IDEXX Laboratories (NASDAQ:IDXX)
Gráfico Histórico do Ativo
De Out 2024 até Nov 2024
IDEXX Laboratories (NASDAQ:IDXX)
Gráfico Histórico do Ativo
De Nov 2023 até Nov 2024
